Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - the major therapeutic target

被引：58

作者：

Pankiewicz, KW ^{[1
]}

Patterson, SE ^{[1
]}

Black, PL ^{[1
]}

Jayaram, HN ^{[1
]}

Risal, D ^{[1
]}

Goldstein, BM ^{[1
]}

Stuyver, LJ ^{[1
]}

Schinazi, RF ^{[1
]}

机构：

[1] Pharmasset Inc, Atlanta, GA 30084 USA

来源：

CURRENT MEDICINAL CHEMISTRY | 2004年 / 11卷 / 07期

关键词：

D O I：

10.2174/0929867043455648

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-a is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin) and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.

引用

页码：887 / 900

页数：14

共 100 条

[1] STUDIES ON THE MECHANISM OF ACTION OF 2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE .5. FACTORS GOVERNING THE RESPONSE OF MURINE TUMORS TO TIAZOFURIN [J].